January 10, 2017
ArtVentive Medical Group Inc. (“ArtVentive”) announced today that Mr. William Olson has joined as its Chief Executive Officer to execute a sales and marketing program to commercialize and distribute its revolutionary blood occlusion device called EOSTM.
EOS TM, now approved by the FDA and received CE Mark, immediately halts blood and fluid flow when deployed in veins, arteries and tubes in the human body and has further potential applications in venous disease, tumor treatment and contraception. The device used by interventional radiologists and vascular surgeons, is a patented device that saves doctors time, hospitals money and reduces exposure to radiation during deployment when used in vascular embolization procedures.
Mr. Olson explained that he “welcomes the challenge and opportunity with ArtVentive team to make EOS TM the standard of care for blood occlusion devices. With estimated addressable market for its current and future products of over an $3 billion, ArtVentive is well positioned to rapidly commercialize its first generation of products and build on its technology platform for innovative treatment. EOS TM and its progeny have the opportunity to become a game changing product in the rapidly growing market of interventional radiology and vascular surgery.”
Mr. Olson is a seasoned med-tech executive with approximately 20 years of operational leadership experience. He previously served as Chief Executive Officer of Satient, a life-science strategic advisory firm based in Menlo Park, California. He was President and Chief Executive Officer of ACT, an electrophysiology catheter developer, and co-founder and Chief Executive Officer of Sawtooth Labs (NASDAQ:AVGR). Mr. Olson also served as Vice President of corporate development at FoxHollow Technologies which was acquired by Medtronic (NASDAQ:MDT). His broad experience also includes direct sales for Guidant’s (NYSE:GDT) Cardiac Rhythm Management division, strategy and operations consulting at Deloitte Consulting and six sigma project management at GE (NYSE:GE) Medical Systems. Mr. Olson holds an MBA from Harvard Business School and undergraduate degrees from Boston College, where he graduated summa cum laude.
Leon Rudakov, PhD, ArtVentive’s founder, President and CTO, stated that “We are excited to welcome Bill to the team. He brings critical management expertise to our team at a time we are expanding and commercializing EOS TM. We have been working together already quite well as a team. He will build the business while I can focus on further developing our technology platform so ArtVentive brings new products to market to fuel long term growth.”
About ArtVentive Medical Group, Inc.
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOS™.
The ArtVentive EOS™ is a catheter based, self-expandable device, which facilitates permanent and immediate occlusion of peripheral vessels. The ArtVentive EOS™ is designed to serve as a safe and reliable alternative to major surgery in certain cases.
Leon Rudakov, PhD
President and CTO
ArtVentive Medical Group, Inc.